MPS III - Sanfilippo — Rare Disease Research Partners

0

Skip to Content

About RDRP

About us

Meet the Senior Leadership Team

RDRP Brochure

Careers

Our Services

Clinical Trials Support

Research and Evidence

Medical Communications

Managed Access Programmes

Advice

Publications

Blog

News

Engaging patient and advocates in rare disease clinical trials

Rare Disease Pocket Knowledge

Case Studies

Clinical Trial Case Studies

Contact

About RDRP

About us

Meet the Senior Leadership Team

RDRP Brochure

Careers

Our Services

Clinical Trials Support

Research and Evidence

Medical Communications

Managed Access Programmes

Advice

Publications

Blog

News

Engaging patient and advocates in rare disease clinical trials

Rare Disease Pocket Knowledge

Case Studies

Clinical Trial Case Studies

Contact

Back

Meet the Senior Leadership Team

RDRP Brochure

Careers

Back

Clinical Trials Support

Research and Evidence

Medical Communications

Managed Access Programmes

Advice

Back

News

Engaging patient and advocates in rare disease clinical trials

Rare Disease Pocket Knowledge

Back

Clinical Trial Case Studies

MPS II - Hunter

MLD

MPS House, Repton Place, White Lion Road, Amersham, Buckinghamshire, HP7 9LP, United Kingdom t. +44 (0) 345 260 1087
e. info@rd-rp.com

Meet the Senior Leadership Team
Careers MPS Society UK

Our Policies Data Protection and Privacy Policy Data Retention and Disposal Policy Bullying and Harassment Policy Sexual Harassment Policy Equality, Diversity and Inclusion Statement Feedback and Complaints Policy

MPS Commercial is a Private Limited Company Registered No 08621283. MPS Commercial trades as Rare Disease Research Partners and is a wholly owned, not for profit subsidiary of the Society for Mucopolysaccharide Diseases (the MPS Society), Registered Charity in England and Wales No 1143472. Rare Disease Research Partners social objectives are to reinvest any surplus to support the mission of the MPS Society to transform the lives of patients through specialist knowledge, support, advocacy and research.